This pathophysiology diagram illustrates the link between HIV-associated gut dysbiosis and the development of Type 1 Diabetes Mellitus (T1DM). The upper section shows the gut lumen with decreased short-chain fatty acid (SCFA)-producing bacteria. An impaired gut barrier is depicted with HIV-infected epithelial cells, leading to a 'leaky gut' and the translocation of microbes and microbial products into the systemic circulation. This translocation triggers two primary pathways: 1) Systemic immune activation via Toll-like receptors (TLRs), involving CD4+/CD8+ T-cells, macrophages, dendritic cells (DCs), and monocytes, which promotes an autoimmune anti-islet response. 2) Direct interaction of microbial products with pancreatic beta cells, triggering intracellular signaling pathways including NOD2, TLR2/MyD88/NF-kB, and TLR3/MyD88. The diagram further highlights the role of Mucosal-Associated Invariant T (MAIT)-cells, which exhibit altered cytotoxicity and regulatory functions under these conditions. The final outcome is pancreatic beta-cell destruction (dead beta-cell) and the cessation of insulin production, illustrating a proposed mechanism for secondary autoimmune diabetes in people living with HIV (PLWH).

A multi-panel educational graphic illustrating the pathophysiology, triggers, and treatments for Type 1 Diabetes Mellitus (T1DM). Panel A is a flowchart showing the immunological pathway from pancreatic stress to autoreactive lymphocyte-mediated beta cell destruction via dendritic cell (DC) migration to lymph nodes. Panel B provides a pathophysiology diagram of a pancreatic islet (50-250 µm). It depicts immune cell infiltration (insulitis) by T cells (gray), leading to the destruction of central beta cells (blue) while non-beta cells (red) remain at the periphery. Panel C summarizes T1DM triggers, including autoantigens (insulin, GAD65), genetic factors (Foxp3, MHC background), and co-incident infections (enteroviruses). Panel D lists current and experimental treatments, categorizing endocrinology approaches (insulin pumps, islet transplantation from hESCs/iPSCs) and immunotherapy strategies (corticosteroids, biologics like IL-2, and adoptive cell transfers including Tregs and MSCs). The graphic serves as a comprehensive overview of T1DM etiology and clinical management.

This pathophysiology diagram compares the disease state of autoimmune diabetes against the therapeutic intervention of LRH-1 agonistic activation. The top panel depicts autoimmune diabetes characterized by a pro-inflammatory immune response (red-dominant pie chart) interacting via a destructive dialogue with pancreatic islets. This results in a shift toward pro-inflammatory factors on a cellular balance scale, leading to insulitis, severe beta-cell destruction, reduced beta-cell mass, and clinical hyperglycemia. The bottom panel illustrates the effects of LRH-1 agonistic activation, which promotes tissue remodeling and an anti-inflammatory/regenerative immune response (blue-dominant pie chart). This intervention shifts the cellular balance toward anti-inflammatory factors, mitigating insulitis and stimulating beta-cell regeneration, specifically via alpha-to-beta cell transdifferentiation. The resulting pancreatic islet shows restored beta-cell mass, leading to a state of normoglycemia. Key educational concepts include the modulation of immune-islet crosstalk and the potential for regenerative medicine in type 1 diabetes mellitus through nuclear receptor signaling.

This pathophysiology diagram illustrates the metabolic pathways linking obesity, adipose tissue, and free fatty acids (FFAs) to insulin resistance and Type 2 diabetes (T2D). The flow is divided into several interconnected mechanisms. On the left, obesity-driven adipose tissue expansion releases proinflammatory cytokines leading to systemic low-grade inflammation, while elevated FFAs induce lipid peroxidation and the accumulation of prostaglandins and ceramides. These metabolites trigger a cycle of endoplasmic reticulum (ER) stress and mitochondrial dysfunction, resulting in elevated reactive oxygen species (ROS) and reactive nitrosative stress (RNS). Together, inflammation and oxidative stress culminate in insulin resistance and T2D. On the right, a comparison chart shows the differential effects of FFA exposure on pancreatic beta-cells: acute FFA exposure increases beta-cell mass and insulin secretion to compensate for insulin insensitivity, whereas chronic FFA exposure decreases beta-cell mass and insulin secretion, leading to lipotoxicity. A central inset further links a Western diet to metabolic dysregulation, encompassing lipotoxicity, inflammation, and insulin resistance as drivers of Type 2 diabetes.

A medical pathophysiology diagram illustrating the link between peripheral insulin resistance (IR) in Type 2 Diabetes Mellitus (T2DM) and brain insulin resistance in Alzheimer's Disease (AD), highlighting the protective role of melatonin. The diagram is split into two sections by a dotted line representing the blood-brain barrier (BBB). The lower section depicts peripheral mechanisms including adipose tissue releasing pro-inflammatory cytokines (IL-1α, TNF-α, IL-3, IFN-γ, MCP-1, MIP-1α, MIP-1β, and NF-κB) and pancreatic alterations (early stage hyperinsulinemia followed by beta-cell failure and decreased insulin secretion). These peripheral cytokines are shown crossing the BBB into the brain. The upper section illustrates central effects: neuroinflammation characterized by IL-6 and TNF-α, mitochondrial dysfunction involving ROS, iNOS, COX-2, and PGC1α, and subsequent brain IR. A molecular structure of melatonin is shown on the left, indicated as an agent that 'prevents' the progression from peripheral IR to central neurodegeneration by targeting insulin signaling pathways.

Summary : This flowchart presents a model for age-related hyperglycemia, illustrating how various risk factors contribute to insulin resistance, decreased pancreatic beta cell function, and ultimately the development of prediabetes and type 2 diabetes. flowchart: # Risk Factors : • Lifestyle • Genetics • Comorbid conditions • Aging • Obesity (resulting from lifestyle) # Nodes : • Resistance to metabolic effects of insulin (rectangle) • Decreased pancreatic beta cell mass/function (rectangle) • Prediabetes (rectangle) • Impaired adaptation to insulin resistance (rectangle) • Type 2 Diabetes (rectangle) # Connectors : • Risk factors (lifestyle, genetics, comorbid conditions, aging) point to both "Resistance to metabolic effects of insulin" and "Decreased pancreatic beta cell mass/function". • "Obesity" (from lifestyle) also points to "Resistance to metabolic effects of insulin". • "Resistance to metabolic effects of insulin" leads to "Prediabetes". • "Decreased pancreatic beta cell mass/function" leads to "Impaired adaptation to insulin resistance". • "Impaired adaptation to insulin resistance" leads to "Prediabetes". • "Prediabetes" leads to "Type 2 Diabetes". • "Type 2 Diabetes" has arrows looping back to both "Resistance to metabolic effects of insulin" and "Decreased pancreatic beta cell mass/function", labeled "Glucose toxicity?". # Layout : • Left column: Risk factors listed in a box. • Middle column: Two parallel nodes ("Resistance to metabolic effects of insulin" and "Decreased pancreatic beta cell mass/function"). • Right column: "Prediabetes" leading to "Type 2 Diabetes". • Lower middle: "Impaired adaptation to insulin resistance" connects "Decreased pancreatic beta cell mass/function" to "Prediabetes". • Feedback loops from "Type 2 Diabetes" to both upstream nodes. # Analysis : • The diagram shows a cyclical and progressive pathway: risk factors increase insulin resistance and decrease beta cell function, leading to prediabetes and type 2 diabetes. • Feedback loops suggest that glucose toxicity from diabetes can further worsen insulin resistance and beta cell dysfunction, creating a vicious cycle. • The model highlights the multifactorial nature of age-related hyperglycemia, with both genetic and lifestyle components, and the central role of impaired insulin adaptation.